Genitourinary Cancer

Results of two studies presented at Genitourinary Cancers Symposium showed treatment with enfortumab vedotin-ejfv benefited patients with locally advanced or metastatic urothelial carcinoma previously treated with a PD-1 or PD-L1 inhibitor.

Elizabeth Plimack, MD, MS, has been appointed chair of Bladder Cancer Advocacy Network’s scientific advisory board.

The FDA approved nivolumab in combination with cabozantinib as first-line treatment of patients with advanced renal cell carcinoma, according to a manufacturer-issued press release.

The FDA granted fast track designation to padeliporfin immune photo activated cancer treatment as treatment for adults with low-grade upper tract urothelial carcinoma.

A urine-based whole-genome sequencing assay demonstrated high specificity and comparable sensitivity to standard cytology for the detection of urothelial carcinoma, according to study results published in Clinical Cancer Research.

Exposure to diagnostic radiation below the waist may increase risk for testicular germ cell tumors, according to results of a case-control study published in PLOS One.

Colleen Tetzlaff, MHS, PA-C, has been named president of Association of Physician Assistants in Oncology.

Most cancer survivors reported experiencing some degree of sexual dysfunction after treatment, yet women were less likely than men to report being asked about sexual health by their health care provider, according to study results.

Single-fraction stereotactic body radiation therapy appeared safe and effective for patients with up to three oligometastatic lung tumors, according to results of the phase 2 SAFRON II trial presented at the virtual ASTRO Annual Meeting.

The overprescribing and overuse of antibiotics has been scrutinized in recent years due to the threat of antimicrobial resistance.